Pharma

Your Article Summary

See Latest Articles

Takeda Receives FDA Complete Response Letter for Alogliptin, An Investigational Treatment for Type 2 Diabetes
Takeda Pharmaceuticals North America, 07/02/09

Takeda Pharmaceutical Company Limited announced that Takeda Global Research and Development Center, Inc., a wholly owned United States subsidiary received on June 26 a complete response letter from the U.S. Food and Drug Administration regarding the Company's New Drug Application for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

Today in Regulatory Issues...keeping you current

Receive free subspecialty "5-minute updates" via email

Review calls for EHR action in Saskatchewan
Canadian Healthcare Technology, 11/20/09

Leavitt Leaving CCHIT
HealthDataManagement, 11/20/09

AzHHAs Rivers to retire in 2011
American Hospital Association News, 11/16/09

 See all of Regulatory Issues